Loading…
Loading…
ICLR does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for ICLR and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for ICLR and 80,000+ other tickers.
See exactly how ICLR's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for ICLR and 80,000+ other tickers.
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management…
Icon PLC (ICLR) reported earnings 30 days ago. What's next for the stock?
On August 19, 2026, Icon PLC (ICLR) shares rose 3.2% today, closing at $172.49, which is within its 52-week range of $66.57 to $203.91. This recent uptick in sh
On August 17, 2026, Icon PLC (ICLR) shares rose 3.9%, bringing the current price to $169.45. This price is situated within a 52-week range of $66.57 to $203.91,
The portfolio's return was 9.21% (net) for the reporting period. Centene, ICON and Keurig Dr Pepper were the contributors during the quarter. Intercontinental Exchange, Salesforce and ConocoPhillips were the detractors during the quarter.
ICLR's discounted valuation and $23.4B backlog support upside potential, but falling estimates, weaker margins and execution risks argue for patience.